F S&P 500
5,211.25 -2.50 (-0.05%) F Dow Jones
39,006.00 -21.00 (-0.05%) F Nasdaq
18,189.25 -10.25 (-0.06%) E-mini Russell 2000 Index Futur
2,070.90 -5.80 (-0.28%) Petróleo
77.97 -0.41 (-0.52%) Oro
2,327.00 +2.80 (+0.12%)
SELLAS Life Sciences Group, Inc. (SLS)
Fuera de horario:
SELLAS Life Sciences Group, Inc.
Times Square Tower
Suite 2503 7 Times Square
New York, NY 10036
United States
646 200 5278
https://www.sellaslifesciences.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 16
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Angelos M. Stergiou M.D., ScD h.c. | Founder, President, CEO & Director | 904.24k | N/D | 1976 |
| Mr. John Thomas Burns CPA | Senior VP & CFO | 505.16k | N/D | 1985 |
| Ms. Stacy E. Yeung | VP, Associate General Counsel & Head of Compliance | N/D | N/D | N/D |
| Dr. Dragan Cicic M.D., MBA | Senior Vice President of Clinical Development | 466.43k | N/D | 1963 |
| Mr. Andrew Elnatan | VP and Head of Regulatory Affairs, Chemistry, Manufacturing and Controls & Quality | N/D | N/D | N/D |
Descripción
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
Gestión corporativa
La calificación ISS Governance QuickScore de SELLAS Life Sciences Group, Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
